Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA).
The approval makes Singapore the first country in Southeast Asia to fully approve the latest COVID-19 vaccine for use in individuals 6 months of age and older. The LP.8.1 sublineage was chosen based on guidance from the US FDA, EMA, and WHO, which stated that LP.8.1 is the preferred sublineage for a monovalent JN.1-lineage-based COVID-19 vaccine for the US beginning in fall 2025.
The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner clinics starting in October 2025. Under Singapore’s comprehensive National Vaccination Programme/NVP, the COVID-19 vaccine remains free of charge for all Singapore Citizens, Permanent Residents, Long-Term Pass Holders, and certain Short-Term Pass holders.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.
BioNTech is a biotech company that develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
